

## SPECIAL FEATURES

### Highlights of This Issue 2465

### CCR Translations

- 2467** Shedding Light on *IDH1* Mutation in Gliomas  
Todd C. Hollon and Daniel A. Orringer  
*See related article, p. 2530*

- 2470** *HER2* Deregulation in Lung Cancer: Right Time to Adopt an Orphan?  
Federico Cappuzzo and Lorenza Landi  
*See related article, p. 2594*

### Reviews

- 2473** Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy  
Dayana B. Rivadeneira and Greg M. Delgoffe
- 2482** Oxidative Phosphorylation as an Emerging Target in Cancer Therapy  
Thomas M. Ashton, W. Gillies McKenna, Leoni A. Kunz-Schughart, and Geoff S. Higgins

### Perspective

- 2491** Leveraging the Success of HIV Drug Development Paradigms for Cancer  
Gideon M. Blumenthal, Debra Birnkrant, and Richard Pazdur

## CANCER THERAPY: CLINICAL

- 2493** Focal Irradiation and Systemic TGF $\beta$  Blockade in Metastatic Breast Cancer  
Silvia C. Formenti, Percy Lee, Sylvia Adams, Judith D. Goldberg, Xiaochun Li, Mike W. Xie, Josephine A. Ratican, Carol Felix, Lin Hwang, Kym F. Faull, James W. Sayre, Sara Hurvitz, John A. Glaspy, Begoña Comin-Anduix, Sandra Demaria, Dörthe Schae, and William H. McBride

- 2505** Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1

Denis Soulières, Lisa Licitra, Ricard Mesía, Éva Remenár, Shau-Hsuan Li, Andrey Karpenko, Marie Chol, Ying A. Wang, Nadia Solovieff, Laurence Bourdeau, Dalila Sellami, and Sandrine Faivre

## PERSONALIZED MEDICINE AND IMAGING

- 2517** ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors  
Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltman, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llombart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, and Carlos L. Arteaga

- 2530** Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the *IDH1* Mutation Status  
Ortrud Uckermann, Tareq A. Juratli, Roberta Galli, Marina Conde, Ralf Wiedemuth, Dietmar Krex, Kathrin Geiger, Achim Temme, Gabriele Schackert, Edmund Koch, Gerald Steiner, and Matthias Kirsch  
*See related commentary, p. 2467*

- 2539** Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture  
Ja Hye Myung, Michael J. Eblan, Joseph M. Caster, Sin-Jung Park, Michael J. Poellmann, Kyle Wang, Kevin A. Tam, Seth M. Miller, Colette Shen, Ronald C. Chen, Tian Zhang, Joel E. Tepper, Bhishamjit S. Chera, Andrew Z. Wang, and Seungpyo Hong

# Table of Contents

## CANCER THERAPY: PRECLINICAL

**2548** Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status

Paul Mésange, Anaïs Bouygues, Nathalie Ferrand, Michèle Sabbah, Alexandre E. Escargueil, Ariel Savina, Benoist Chibaudel, Christophe Tournigand, Thierry André, Aimery de Gramont, and Annette K. Larsen

**2559** IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma



Erik Ladomersky, Lijie Zhai, Alicia Lenzen, Kristen L. Lauing, Jun Qian, Denise M. Scholtens, Galina Gritsina, Xuebing Sun, Ye Liu, Fenglong Yu, Wenfeng Gong, Yong Liu, Beibei Jiang, Tristin Tang, Ricky Patel, Leonidas C. Plataniias, C. David James, Roger Stupp, Rimas V. Lukas, David C. Binder, and Derek A. Wainwright

**2574** Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma

Hiroshi Nakashima, Tran Nguyen, Kazue Kasai, Carmela Passaro, Hirotaka Ito, William F. Goins, Imran Shaikh, Ronald Erdelyi, Reiko Nishihara, Ichiro Nakano, David A. Reardon, Ana C. Anderson, Vijay Kuchroo, and E. Antonio Chiocca

**2585** Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model

Ferro Nguyen, Ivan Alferiev, Peng Guan, David T. Guerrero, Venkatadri Kolla, Ganesh S. Moorthy, Michael Chorny, and Garrett M. Brodeur

**2594** Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib



Shengwu Liu, Shuai Li, Josephine Hai, Xiaoen Wang, Ting Chen, Max M. Quinn, Peng Gao, Yanxi Zhang, Hongbin Ji, Darren A.E. Cross, and Kwok-Kin Wong  
*See related commentary, p. 2470*

**2605** Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers

Elisabetta Marangoni, Cécile Laurent, Florence Coussy, Rania El-Botty, Sophie Château-Joubert, Jean-Luc Servely, Ludmilla de Plater, Franck Assayag, Ahmed Dahmani, Elodie Montaudon, Fariba Nemati, Justine Fleury, Sophie Vacher, David Gentien, Audrey Rapinat, Pierre Foidart, Nor Eddine Sounni, Agnès Noel, Anne Vincent-Salomon, Marick Lae, Didier Decaudin, Sergio Roman-Roman, Ivan Bièche, Martine Piccart, and Fabien Reyat

**2616** The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis

Michael D. Deel, Katherine K. Slemmons, Ashley R. Hinson, Katia C. Genadry, Breanne A. Burgess, Lisa E.S. Crose, Nina Kuprasertkul, Kristianne M. Oristian, Rex C. Bentley, and Corinne M. Linardic

**2631** Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Olivia Campagne, Audrey Delmas, Sylvain Fouliard, Marylore Chenel, Gurunadh R. Chichili, Hua Li, Ralph Alderson, Jean-Michel Scherrmann, and Donald E. Mager

**2642** Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth *In Vivo*

Robert A. Fenstermaker, Sheila A. Figel, Jingxin Qiu, Tara A. Barone, Sanam S. Dharma, Evan K. Winograd, Phillip M. Galbo, Laura M. Wiltsie, and Michael J. Ciesielski

**2653** B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Kimio Yonesaka, Koji Haratani, Shiki Takamura, Hitomi Sakai, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Sigeki Kato, Osamu Maenishi, Kazuko Sakai, Yasutaka Chiba, Takafumi Okabe, Keita Kudo, Yoshikazu Hasegawa, Hiroyasu Kaneda, Michiko Yamato, Kenji Hirotani, Masaaki Miyazawa, Kazuto Nishio, and Kazuhiko Nakagawa

**2665** STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner

Shanshan Sun, Yansheng Wu, Wenyu Guo, Feng Yu, Lingping Kong, Yu Ren, Yu Wang, Xiaofeng Yao, Chao Jing, Chao Zhang, Mingyang Liu, Yuqing Zhang, Minghui Zhao, Zhaoqing Li, Chuanqiang Wu, Yu Qiao, Jingxuan Yang, Xudong Wang, Lun Zhang, Min Li, and Xuan Zhou

## BIOLOGY OF HUMAN TUMORS

**2678** Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma



David G.P. van IJzendoorn, Stefan Sleijfer, Hans Gelderblom, Ferry A.L.M. Eskens, Geert J.L.H. van Leenders, Karoly Szuhai, and Judith V.M.G. Bovée

# Table of Contents

**2688** Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma

Joanna Przybyl, Jacob J. Chabon, Lien Spans, Kristen N. Ganjoo, Sujay Vennam, Aaron M. Newman, Erna Forgó, Sushama Varma, Shirley Zhu, Maria Debiec-Rychter, Ash A. Alizadeh, Maximilian Diehn, and Matt van de Rijn

**2700** Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells


Xueheng Zhao, Marion G. Brusadelli, Sharon Sauter, Melinda Butsch Kovacic, Wujuan Zhang, Lindsey E. Romick-Rosendale, Paul F. Lambert, Kenneth D.R. Setchell, and Susanne I. Wells

 AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows a histological section of an excisional biopsy from a patient with pseudomyogenic hemangioendothelioma, where the lesion is localized in the dermis. The patient showed complete and durable remission to treatment with telatinib. The mechanism behind this response was elucidated using an *in vitro* model for pseudomyogenic hemangioendothelioma. For details, see the article by van IJzendoorn and colleagues on page 2678 of this issue.



# Clinical Cancer Research

**24 (11)**

*Clin Cancer Res* 2018;24:2465-2709.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/24/11>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/24/11>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.